Samsung Group in talks to buy Biogen (BIIB) - Korean Economic Daily

Samsung Group is in talks to buy Biogen (NASDAQ: BIIB) for more than $40 billion, the Korean Economic Daily reported Wednesday afternoon citing investment banking sources.

The report said Biogen approached Samsung about a deal valued at around $42 billion. Biogen's current market cap is around $35 billion.

"Samsung is at the negotiating table with the sell side to acquire Biogen," a senior official at a global investment bank told The Korea Economic Daily on Dec. 29.

A spokesperson for Biogen told StreetInsider.com it does not comment on market rumors or speculation related to rumors Samsung Group is in talks to buy it.

You May Also Be Interested In

• Lyft to acquire Serveo's bikeshare business in Spain
• Tarsus acquires iRenix Medical for up to $565M in eye care deal
• Blue Owl Capital completes acquisition of 12 Spire Healthcare hospitals